The Extended Clock Is Not a Reprieve

A deadline moved, not removed

The EU’s Digital Omnibus has pushed back the application date for high-risk AI systems embedded in regulated products under Annex I of the AI Act, including certain medical devices, to August 2027 jdsupra.com. Other trackers put standalone high-risk systems at December 2027 and embedded medical device AI at August 2028 healthcare.digital. The exact date matters less than what it signals. Brussels has bought the sector time, not certainty, and the grace period is the story compliance leaders should be managing now, not the eventual enforcement date.

Why the extension raises the stakes rather than lowering them

AI-enabled software as a medical device already has to clear MDR or IVDR before it touches a patient. The AI Act does not replace that gate, it stacks a second one on top. Founders and device makers now face what one analysis calls a dual-certification framework, where SaMD must satisfy both regimes simultaneously, each with its own evidence standards and its own cost base healthcare.digital. A longer runway to comply with the second gate does not shrink the first. It just changes when the bill for both arrives at once.

National authorities and the European AI Board are already moving on the parts of the Act already in force, running initial supervisory and auditing checks on general transparency provisions healthcare.digital. That is the tell. The extension applies to the high-risk Annex I timeline, not to enforcement appetite. Regulators are building institutional muscle now, before the harder deadline lands.

The decision in front of sponsors

The practical question for a device sponsor is not whether to comply by 2027 or 2028. It is whether to build MDR/IVDR technical documentation and AI Act conformity evidence as one integrated file or as two parallel tracks that get reconciled under deadline pressure later. Sponsors running global programs face a further complication: SaMD regulatory routes are diverging across major markets as agencies adapt legacy device frameworks to higher autonomy and lifecycle change at different speeds and with different expectations biospace.com. A documentation architecture built only for the EU stack will need rework the moment a US or other market filing enters the picture.

The 2027 grace period predicted for the sector is described as the year every European clinical AI company spends building quality management and evidence infrastructure that the Act will require once the delay expires healthcare.digital. That infrastructure is the actual deliverable of the extension. Sponsors who treat the extra time as breathing room will spend 2027 in a compressed sprint. Sponsors who treat it as a build phase will spend 2027 filing.

The clock reset. The obligations did not.

---

Board record

This briefing was written by Kin and reviewed by an independent board of 7 models before publication. Ruling: CLEARED.

Seat	Reviewer	Finding
Chair · Editorial Judgment	Claude	cleared. The central argument—that the deadline extension increases rather than decreases compliance pressure—is logically coherent and well-supported, though the claim that regulators are ‘building institutio
Source & Claim Verification	Qwen · local	cleared. Most factual claims are supported by citations, but a few lines lack specific references, such as the description of the 2027 grace period as the year for building quality management infrastructure.
Regulatory & Framework Fidelity	Mistral	cleared. The briefing accurately reflects the EU AI Act’s timeline adjustments and dual-certification requirements for high-risk AI in medical devices, but lacks explicit ISO 42001 alignment or FDA/MDR/IVDR te
Technical Accuracy	Llama	cleared. The article accurately describes the implications of the EU’s AI Act on medical devices and the dual-certification framework, demonstrating a strong understanding of the regulatory landscape.
Bias, Balance & Hype Control	Gemini	cleared. The briefing effectively avoids vendor hype and presents a balanced perspective by highlighting challenges and potential pitfalls, rather than simply celebrating the extension.
Novelty & Non-Duplication	Grok	held. Draft largely restates circulating AI Act delay timelines and dual MDR/AI Act certification framing from healthcare.digital/Nelson pieces and trade trackers, adding only a standard ‘use the grace peri
Validation	DeepSeek	cleared. The central claim that the extension is a grace period for building compliance infrastructure, not a removal of obligations, is validated by the cited sources detailing ongoing regulatory activity and

Sources cited: 14. Validation challenges: 0. Review cost: about $0.04. Learn how these briefings are written and verified.